3TBA: An Early Feasibility Evaluation of a Novel 3rdMolarTooth Bud Ablation Procedure

Sponsor
TriAgenics Inc (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT05374993
Collaborator
(none)
10
1
9

Study Details

Study Description

Brief Summary

This single-arm prospective study will enroll a minimum of 7 and a maximum 10 subjects between the ages of 7 and 13 years of age with radiographic evidence of mandibular 3rd molar tooth bud development without enamel formation. Each subject will undergo a 3TBA procedure for each qualifying mandibular 3rd molar tooth buds. Each subject will receive treatment for qualifying mandibular tooth buds during the same session. Subjects will be followed for a minimum of 12 weeks post treatment.

Condition or Disease Intervention/Treatment Phase
  • Device: 3TBA
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
10 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
Single-arm prospective studySingle-arm prospective study
Masking:
None (Open Label)
Primary Purpose:
Device Feasibility
Official Title:
An Early Feasibility Evaluation of a Novel 3rdMolarTooth Bud Ablation Procedure
Anticipated Study Start Date :
Oct 1, 2022
Anticipated Primary Completion Date :
Jul 1, 2023
Anticipated Study Completion Date :
Jul 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: 3TBA Procedure

Device: 3TBA
Induce third molar tooth bud agenesis

Outcome Measures

Primary Outcome Measures

  1. Tooth Structure Development Assessment [12 weeks]

    Efficacy assessment will be performed based on periapical X-rays from Follow-up Visit 3 (12-week post treatment). Effectiveness Assessment will consist of evaluation of Tooth Structure Development and Bony Crypt In Growth using the following scale. Tooth Structure Development Assessment Scale for 3rd Molar: "0" = No radiographic evidence. "1" = Minimal or trace level of detectable radiographic evidence. "2" = Moderate or intermediate level of detectable radiographic evidence of mineralized tooth structure formation with crown formation to be less than 50% complete. "3" = Advanced level of detectable radiographic evidence of mineralized tooth structure formation with enamel formation estimated to be 50% or more complete. Success is defined as a score of "0" or "1" on Tooth Structure Development scale at Follow-up Visit 3 (12-week post treatment). Each treated tooth bud is evaluated individually.

  2. Bony Crypt Growth Assessment [12 weeks]

    Efficacy assessment will be performed based on periapical X-rays from Follow-up Visit 3 (12-week post treatment). Effectiveness Assessment will consist of evaluation of Bony Crypt In Growth using the following scales. Tooth Structure Development Assessment Scale for 3rd Molar: "0" = No radiographic evidence. "1" = Minimal or trace level of detectable radiographic evidence of mineralized tooth structure formation. "2" = Moderate or intermediate level of detectable radiographic evidence of mineralized tooth structure formation with crown formation to be less than 50% complete. "3" = Advanced level of detectable radiographic evidence of mineralized tooth structure formation with enamel formation estimated to be 50% or more complete. N/I = Not Interpretable. N/A = Not Applicable. Success is defined as a score of "0" or "1" on Bony Crypt Growth Assessment scales at Follow-up Visit 3 (12-week post treatment). Each treated tooth bud is evaluated individually.

Secondary Outcome Measures

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] [12 weeks]

    Proximal second molars continue to erupt normally Proximal second molars have no radiographic evidence of crown alteration Surgical site is completely healed over on visual exam Radiographic assessment of the surgical site is WNL expected or post op healing No adverse events related to the 3TBA procedure No reported neurological changes to tongue or lip

Eligibility Criteria

Criteria

Ages Eligible for Study:
7 Years to 13 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. Subject is between 7 and 13 years of age

  2. Subject has radiographic evidence of at least one mandibular 3rd molar tooth bud

Exclusion Criteria:
  1. Subject use of articaine is contraindicated (known hypersensitive to products containing sulfites).

  2. Subject has any condition which, in the opinion of the Investigator, would prevent adequate performance of the procedure or affect the health and/or safety of the subject.-

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • TriAgenics Inc

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
TriAgenics Inc
ClinicalTrials.gov Identifier:
NCT05374993
Other Study ID Numbers:
  • TP-015
First Posted:
May 16, 2022
Last Update Posted:
Jul 25, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes

Study Results

No Results Posted as of Jul 25, 2022